Literature DB >> 11177663

Clinical trial evidence for the cardioprotective effects of omega-3 fatty acids.

W S Harris1, W L Isley.   

Abstract

The notion that marine omega (w)-3 fatty acids might have beneficial cardiovascular effects was first suggested by epidemiologic studies in Greenland Inuits published in the late 1970s. These simple observations spawned hundreds of other studies, the confluence of which strongly suggests a true cardioprotective effect of w-3 fatty acids. The strongest confirmation has come from the publication of three randomized clinical trials, all of which reported benefits to patients with preexisting coronary artery disease. The most convincing of these was the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevezione study, in which 5654 patients with coronary artery disease were randomized to either w-3 fatty acids (850 mg/d) or usual care. After 3.5 years, those taking the w-3 fatty acids had experienced a 20% reduction in overall mortality and a 45% decrease in risk for sudden cardiac death. These findings support the view that relatively small intakes of w-3 fatty acids are indeed cardioprotective, and suggest that they may operate by stabilizing the myocardium itself.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11177663     DOI: 10.1007/s11883-001-0055-2

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  28 in total

1.  Diet and reinfarction.

Authors:  M L Burr; P M Sweetham; A M Fehily
Journal:  Eur Heart J       Date:  1994-08       Impact factor: 29.983

Review 2.  Antiarrhythmic effects of polyunsaturated fatty acids. Recent studies.

Authors:  J X Kang; A Leaf
Journal:  Circulation       Date:  1996-10-01       Impact factor: 29.690

Review 3.  Marine oils and cardiovascular reactivity.

Authors:  J P Chin
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1994-05       Impact factor: 4.006

4.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

5.  Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.

Authors:  M de Lorgeril; P Salen; J L Martin; I Monjaud; J Delaye; N Mamelle
Journal:  Circulation       Date:  1999-02-16       Impact factor: 29.690

6.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

7.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

8.  The effect of dietary supplementation of fish oil on experimental myocardial infarction.

Authors:  B R Culp; W E Lands; B R Lucches; B Pitt; J Romson
Journal:  Prostaglandins       Date:  1980-12

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest.

Authors:  D S Siscovick; T E Raghunathan; I King; S Weinmann; K G Wicklund; J Albright; V Bovbjerg; P Arbogast; H Smith; L H Kushi
Journal:  JAMA       Date:  1995-11-01       Impact factor: 56.272

View more
  6 in total

1.  Human biomonitoring to optimize fish consumption advice: reducing uncertainty when evaluating benefits and risks.

Authors:  Scott M Arnold; Tracey V Lynn; Lori A Verbrugge; John P Middaugh
Journal:  Am J Public Health       Date:  2005-03       Impact factor: 9.308

Review 2.  Alternative therapies for diabetes and its cardiac complications: role of vanadium.

Authors:  Tod A Clark; Justin F Deniset; Clayton E Heyliger; Grant N Pierce
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

Review 3.  Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies.

Authors:  D C Chan; J Pang; G Romic; G F Watts
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

Review 4.  Are omega-3 fatty acids the most important nutritional modulators of coronary heart disease risk?

Authors:  William S Harris
Journal:  Curr Atheroscler Rep       Date:  2004-11       Impact factor: 5.113

Review 5.  Adverse Effects of Nutraceuticals and Dietary Supplements.

Authors:  Martin J J Ronis; Kim B Pedersen; James Watt
Journal:  Annu Rev Pharmacol Toxicol       Date:  2017-10-06       Impact factor: 13.820

6.  Novel regulatory roles of omega-3 fatty acids in metabolic pathways: a proteomics approach.

Authors:  Abeer A Ahmed; Kayode A Balogun; Natalia V Bykova; Sukhinder K Cheema
Journal:  Nutr Metab (Lond)       Date:  2014-01-17       Impact factor: 4.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.